Recently, studies from our group have shown that IN co-delivery of miR18a and NEO100 improved the pharmacokinetic profile of miR18a without affecting its pharmacological properties in an Mgp−/− mouse model of arteriovenous malformation (AVM) [39]. The gene discussed is MGP; the disease is arteriovenous hemangioma/malformation.